Overall Survival with Osimertinib in Resected EGFR -Mutated NSCLC

医学 奥西默替尼 内科学 危险系数 安慰剂 临床终点 肺癌 养生 人口 肿瘤科 外科 置信区间 癌症 临床试验 表皮生长因子受体 病理 替代医学 埃罗替尼 环境卫生
作者
Masahiro Tsuboi,Roy S. Herbst,Thomas John,Terufumi Kato,Margarita Majem,Christian Grohé,Jie Wang,Jonathan Wade Goldman,Shun Lü,Wu‐Chou Su,Filippo de Marinis,Frances Alice Shepherd,Ki Hyeong Lee,Nhieu Thi Le,Arunee Dechaphunkul,Dariusz Mirosław Kowalski,Lynne Poole,Ana Bolanos,Yuri Rukazenkov,Yi-Long Lung Cancer Wu
出处
期刊:The New England Journal of Medicine [Massachusetts Medical Society]
卷期号:389 (2): 137-147 被引量:667
标识
DOI:10.1056/nejmoa2304594
摘要

BACKGROUND: )-mutated, stage IB to IIIA non-small-cell lung cancer (NSCLC), adjuvant osimertinib therapy, with or without previous adjuvant chemotherapy, resulted in significantly longer disease-free survival than placebo in the ADAURA trial. We report the results of the planned final analysis of overall survival. METHODS: In this phase 3, double-blind trial, we randomly assigned eligible patients in a 1:1 ratio to receive osimertinib (80 mg once daily) or placebo until disease recurrence was observed, the trial regimen was completed (3 years), or a discontinuation criterion was met. The primary end point was investigator-assessed disease-free survival among patients with stage II to IIIA disease. Secondary end points included disease-free survival among patients with stage IB to IIIA disease, overall survival, and safety. RESULTS: Of 682 patients who underwent randomization, 339 received osimertinib and 343 received placebo. Among patients with stage II to IIIA disease, the 5-year overall survival was 85% in the osimertinib group and 73% in the placebo group (overall hazard ratio for death, 0.49; 95.03% confidence interval [CI], 0.33 to 0.73; P<0.001). In the overall population (patients with stage IB to IIIA disease), the 5-year overall survival was 88% in the osimertinib group and 78% in the placebo group (overall hazard ratio for death, 0.49; 95.03% CI, 0.34 to 0.70; P<0.001). One new serious adverse event, pneumonia related to coronavirus disease 2019, was reported after the previously published data-cutoff date (the event was not considered by the investigator to be related to the trial regimen, and the patient fully recovered). Adjuvant osimertinib had a safety profile consistent with that in the primary analysis. CONCLUSIONS: -mutated, stage IB to IIIA NSCLC. (Funded by AstraZeneca; ADAURA ClinicalTrials.gov number, NCT02511106.).
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
大与小房完成签到,获得积分10
刚刚
等待的含灵完成签到 ,获得积分10
刚刚
今后的应助被朱朱采纳,获得10
1秒前
1秒前
漫漫发布了新的文献求助10
1秒前
sttise完成签到 ,获得积分10
1秒前
run发布了新的文献求助10
1秒前
2秒前
3秒前
3秒前
3秒前
77发布了新的文献求助10
3秒前
木子姗完成签到,获得积分10
3秒前
精明怜南发布了新的文献求助30
4秒前
Sean完成签到,获得积分10
4秒前
TAOS完成签到,获得积分10
4秒前
xiaobo发布了新的文献求助30
4秒前
corleeang发布了新的文献求助10
5秒前
南宫古伦完成签到 ,获得积分10
5秒前
勤恳的向日葵完成签到,获得积分10
5秒前
雪碧关注了科研通微信公众号
5秒前
5秒前
在水一方的应助被xiaoyi采纳,获得10
6秒前
6秒前
6秒前
xixidong完成签到,获得积分10
6秒前
liu完成签到,获得积分20
7秒前
天天快乐的应助被wyyyy采纳,获得10
7秒前
MADAO发布了新的文献求助30
8秒前
寂寞的雁山完成签到,获得积分10
8秒前
知之发布了新的文献求助10
9秒前
9秒前
9秒前
9秒前
李健的应助被醉熏的寄松采纳,获得10
9秒前
一澡干菜完成签到,获得积分10
9秒前
缥缈不惜发布了新的文献求助10
9秒前
朱朱完成签到,获得积分10
10秒前
10秒前
10秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
Boundaries and Bodhisattvas 500
高分子基功能界面水蒸发材料与应用研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8182102
求助须知:如何正确求助?哪些是违规求助? 9571775
关于积分的说明 21819723
捐赠科研通 7778500
什么是DOI,文献DOI怎么找? 3433617
关于科研通互助平台的介绍 2557786
邀请新用户注册赠送积分活动 2479651